Natco Pharma share climbs 7% as firm seeks nod for COVID-19 drug
Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication, according to a press release from Natco26-04-2021